HS-248

N/A

Report date: 2023/02/25 19:25:22
NME

Base Information

Drug NameHS-248
Drug Alias NameHS-248
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase gamma inhibitorsCD8-positive T-Lymphocytes stimulants
TargetsPhosphatidylinositol-4,5-Bisphosphate 3 kinase gamma
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHanhui Pharmaceuticals Company Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHanhui Pharmaceuticals Company Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A